Article info
Scientific Abstracts
Oral Presentations
Vaccination in rheumatic diseases with lessons from COVID
OP0192 SEROLOGICAL RESPONSE AND SAFETY OF A THREE-DOSE SARS-CoV-2 VACCINATION STRATEGY IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES ON IMMUNOSUPPRESSIVE THERAPY
Citation
OP0192 SEROLOGICAL RESPONSE AND SAFETY OF A THREE-DOSE SARS-CoV-2 VACCINATION STRATEGY IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES ON IMMUNOSUPPRESSIVE THERAPY
Publication history
- First published May 23, 2022.
Online issue publication
June 01, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.